Immuron plans phase 2 trial for imm-529 following fda review

Key points immuron completes pre-ind meeting with fda on the development of imm-529 as product to specifically prevent or treat clostridioides difficile infection (cdi) previous clinical trial data on imm-529 provides support for continued development of imm-529 investigational new drug (ind) application for imm-529 planned for 1h 2025 melbourne, australia, sept. 05, 2024 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company, is pleased to announce that it has received favourable feedback from the united states food and drug administration (fda) on the pre-ind (investigational new drug) information package to support the clinical development of imm-529.
IMRN Ratings Summary
IMRN Quant Ranking